Validation Data Gallery
Tested Applications
| Positive FC detected in | mouse splenocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
98274-1-RR targets CD229/SLAMF3 in FC applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant protein 相同性解析による交差性が予測される生物種 |
| Full Name | lymphocyte antigen 9 |
| Calculated molecular weight | 73 kDa |
| GenBank accession number | NM_001277968.1 |
| Gene Symbol | Ly9 |
| Gene ID (NCBI) | 17085 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purfication |
| UNIPROT ID | Q01965 |
| Storage Buffer | PBS with 0.09% sodium azide , pH 7.3 |
| Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
Background Information
Signaling lymphocytic activation molecule 3 (SLAMF3), also known as CD229 or Ly9, is a type I transmembrane glycoprotein that belongs to the SLAM family receptors (PMID: 10970093; 15905546). It is composed of an extracellular region, which consists of four Ig-like domains, a transmembrane region, and a cytoplasmic tail, which includes two immunoreceptor tyrosine-based signaling motifs (ITSMs) and other tyrosine residues that act as binding sites for the SH2 structural domains (PMID: 8537117; 11369645; 38626547). SLAMF3 is mainly expressed in immune cells, such as T, B, and natural killer cells, and it is involved in the fundamental activation and suppression of these immune cells, as well as the regulation of complex immune networks (PMID: 38626547).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CD229/SLAMF3 antibody 98274-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |